Cardiovascular Function in Adult Survivors of Childhood Malignancies
Launched by THE UNIVERSITY OF HONG KONG · Aug 11, 2011
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
Incorporation of anthracyclines into chemotherapy protocols has improved the survival of children with solid tumours and haematological malignancies. Nonetheless, longitudinal studies have implicated the absence of a safe anthracycline dose that is free of cardiotoxicity. Substantial risk for cardiovascular disease has been shown recently in large cohorts of adult survivors of childhood and adolescent survivors. Serial monitoring of cardiac function is hence of paramount importance in childhood cancer survivors for early detection of myocardial damage and timely institution of interventions...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients aged 18 to 35 years old
- • history of acute leukaemia diagnosed before 18 years old
- • completion of cancer directed therapy for at least 5 years.
- Exclusion Criteria:
- • history of congenital heart disease
- • presence of syndromal disorder such as Down syndrome, neurofibromatosis, etc,
- • hypothyroidism not on replacement therapy
- • claustrophobia or other reasons rendering MRI assessment not feasible.
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China
Patients applied
Trial Officials
Yiu-fai Cheung, MD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials